Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
ESMO Open
|
September 20, 2021
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study
D Planchard, P-H Feng, N Karaseva, et al.
ESMO Open
|
January 8, 2025
Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications
C Park, R Kim, J M Bae, et al.
Journal of Clinical Pharmacy and Therapeutics
|
March 3, 2017
Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea
Y J Jeong, H Kim, S J Baik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2012
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
J-L Lee, J-H Ahn, H Y Lim, et al.
Leukemia
|
July 21, 2006
Gene expression signatures associated with the resistance to imatinib
Y-J Chung, T-M Kim, D-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 17, 2017
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma
J-K Lee, S Louzada, Y An, et al.
AJNR. American Journal of Neuroradiology
|
September 29, 2022
Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study
H Chung, H Seo, S H Choi, et al.
Oncogene
|
May 27, 2014
Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development
H-M Yun, M H Park, D H Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
S-H Lee, J-K Lee, M-J Ahn, et al.
AJNR. American Journal of Neuroradiology
|
December 7, 2019
Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value
I Hwang, S H Choi, C-K Park, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
ESMO Open
|
September 20, 2021
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study
D Planchard, P-H Feng, N Karaseva, et al.
ESMO Open
|
January 8, 2025
Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications
C Park, R Kim, J M Bae, et al.
Journal of Clinical Pharmacy and Therapeutics
|
March 3, 2017
Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea
Y J Jeong, H Kim, S J Baik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2012
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
J-L Lee, J-H Ahn, H Y Lim, et al.
Leukemia
|
July 21, 2006
Gene expression signatures associated with the resistance to imatinib
Y-J Chung, T-M Kim, D-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 17, 2017
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma
J-K Lee, S Louzada, Y An, et al.
AJNR. American Journal of Neuroradiology
|
September 29, 2022
Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study
H Chung, H Seo, S H Choi, et al.
Oncogene
|
May 27, 2014
Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development
H-M Yun, M H Park, D H Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
S-H Lee, J-K Lee, M-J Ahn, et al.
AJNR. American Journal of Neuroradiology
|
December 7, 2019
Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value
I Hwang, S H Choi, C-K Park, et al.
Page
of 5